Ophthalmology Xagena

Xagena Mappa
Xagena Newsletter

Dry eye syndrome: treatment with alpha-Linolenic acid

Research conducted by Reza Dana, at the Massachusetts Eye and Ear Infirmary ( MEEI ) Cornea Service, and colleagues at the Schepens Eye Research Institute, have found for the first time that topical drop application of alpha-Linolenic acid ( ALA ) led to a significant decrease in clinical signs of dry eye syndrome in animal models.

ALA is a fatty acid that cannot be made by the body and must be supplied in the diet.

The study is published in the Archives of Ophthalmology.

Dry eye syndrome is a condition in which the eyes do not produce enough tears, causing them to become dry and irritated. Inflammation is frequently associated with the condition. Symptoms of dry eye syndrome include eye discomfort, such as stinging or burning, eye irritation or a feeling of scratchiness.
The condition affects well more than 10 million people, primarily women, in the United States alone and can often lead to problems with activities such as reading and driving.
Unfortunately, treatment options are quite limited in terms of both efficacy and undesirable side-effects.

The study tested three formulations of fatty acids: 0.2 percent alpha-Linolenic acid ( an omega-3 fatty acid ); 0.2 percent linoleic acid ( an omega-6 fatty acid ); and 0.1 percent alpha-Linolenic acid combined with 0.1 percent Linoleic acid.
An eye drop containing each of the three formulations was applied topically to the eye of a mouse once daily.
An untreated group did not receive eye drops.

Signs of dry eye were then measured 24 hours after the last dose. Eyes treated with ALA showed a significant reversal in epithelial damage to the cornea, the transparent dome that covers the pupil.

Results showed a beneficial effect of the topical application of ALA in reversing the signs of dry eye syndrome as well as the inflammatory changes seen in dry eye syndrome.

“ The current study for the first time demonstrates the benefit of topical application of a particular fatty acid in treating the signs of dry eye syndrome at both the molecular and cellular levels. Using topical formulations of fatty acids to treat dry eye would allow for more flexibility for treatment, including lessening side effects that patients can experience from oral intake of fatty acids. Clinical studies with topical fatty acids are being planned, which if successful could alter the method by which this common condition is treated,” said Dana.

Source: Harvard Medical School, 2008